A randomized trial of pegylated-interferon-alpha2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin.

Ciancio A, Picciotto A, Giordanino C, Smedile A, Tabone M, Manca A, Marenco G, Garbagnoli P, Andreoni M, Cariti G, Calleri G, Sartori M, Cusumano S, Grasso A, Rizzi R, Gallo M, Basso M, Anselmo M, Percario G, Ciccone G, Rizzetto M, Saracco G.

Aliment Pharmacol Ther 2006; 24: 1079-86.

http://www.ncbi.nlm.nih.gov/pubmed/16984502